title: Safety and Abuse Liability of Oxazepam: Is This Benzodiazepine Drug Underutilized?
abstract: Benzodiazepine drugs are controversial because of safety and abuse liability concerns, although they have clinically relevant pharmacological differences. The current article reviews studies pertaining to the pharmacology, safety, and abuse liability of oxazepam. Compared to other benzodiazepine drugs, oxazepam has a favorable safety and abuse liability profile, which may be related to its pharmacology. Oxazepam is more slowly absorbed and enters the brain more slowly than other benzodiazepine drugs; it does not have active metabolites and does not accumulate with chronic dosing; its metabolism is not affected by age or by mild/moderate liver disease; and it is not prone to drug-drug interactions. Oxazepam also binds to the translocator protein, which stimulates the synthesis of neurosteroids, and this effect may contribute to its reduced abuse liability.
authors.forename: Robert H
authors.initials: RH
authors.lastname: Howland
mesh_terms: D001569:Benzodiazepines / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology*; D018757:GABA Modulators / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D010076:Oxazepam / Q000009:adverse effects / Q000494:pharmacology*; D012449:Safety / Q000331:legislation & jurisprudence; D019966:Substance-Related Disorders / Q000517:prevention & control
chemical_list: D018757:GABA Modulators; D001569:Benzodiazepines; D010076:Oxazepam